Partnering for Production: CDMOs and Biomanufacturing Strategy

Takeaway: The decision to "make" versus "buy" your manufacturing capacity is one of the most critical strategic choices you will make, requiring a careful balancing of capital efficiency, technical control, and long-term supply chain security.

Your company has developed a robust, scalable biomanufacturing process. Now you face a monumental strategic decision: do you invest the massive capital required to build your own manufacturing plant, or do you partner with a specialized third-party manufacturer to produce your product for you? This is the classic "make vs. buy" dilemma, and the path you choose will have profound implications for your company's finances, operations, and future.

The "buy" option involves partnering with a Contract Development and Manufacturing Organization (CDMO). These are specialized service providers who have the facilities, equipment, and expertise to produce biological products for multiple clients. For many startups, especially in the early stages, partnering with a CDMO is the most logical and capital-efficient path forward.

The Case for "Buying": The CDMO Advantage

  • Capital Efficiency: This is the overwhelming advantage. Building a GMP-compliant biomanufacturing facility can cost anywhere from tens to hundreds of millions of dollars. Partnering with a CDMO allows you to avoid this massive upfront capital expenditure, preserving your precious equity capital for core R&D and clinical development.

  • Speed to Market: A CDMO has an existing facility and a trained workforce. Tech-transferring your process into their plant is significantly faster than designing, constructing, validating, and staffing your own facility from scratch.

  • Access to Expertise: Established CDMOs have deep experience in scaling processes for a wide range of products. You can leverage their hard-won knowledge of manufacturing, quality control, and regulatory compliance.

The Case for "Making": The In-House Advantage

While using a CDMO is often the right choice for early-stage production, many companies ultimately decide to bring manufacturing in-house as they mature.

  • Control and Flexibility: When you own the facility, you have complete control over your production schedule and priorities. You are not competing for a manufacturing slot with a CDMO's other clients. This flexibility can be critical when responding to unexpected clinical trial results or changes in market demand.

  • IP and Know-How Protection: Your manufacturing process is a valuable trade secret. While CDMO contracts have strong confidentiality clauses, keeping your process entirely within your own four walls provides the highest possible level of protection for your know-how.

  • Long-Term Cost of Goods (COGS): While the upfront CapEx is high, owning your own facility can lead to a lower per-unit production cost in the long run, as you are not paying the CDMO's profit margin on every batch.

A Hybrid Strategy: The Best of Both Worlds

Many companies adopt a hybrid strategy that evolves over time.

  1. Early Stage (Phase 1/2): Rely on a CDMO for initial clinical supply. This is fast and capital-efficient.

  2. Late Stage (Phase 3/Commercial): Having validated the product in the clinic, make the strategic decision to build your own facility to secure your long-term supply chain and control your costs for the commercial launch.

The decision to make versus buy is a complex one with no single right answer. It requires a careful analysis of your company's financial resources, technical capabilities, and long-term strategic goals. Whether you choose to partner or to build, the key is to ensure you have a secure, reliable, and compliant supply of your product to meet the needs of your patients and customers.

Disclaimer: This post is for general informational purposes only and does not constitute legal, tax, or financial advice. Reading or relying on this content does not create an attorney–client relationship. Every startup’s situation is unique, and you should consult qualified legal or tax professionals before making decisions that may affect your business.

Next Post